A Study of Molecular Anatomic Imaging Analysis of Tau, the Primary Pathological Protein in Progressive Supranuclear Palsy

Overview

About this study

The purpose of this study is to learn more about the distribution of the pathological protein tau in the living brains of patients with Progressive Supranuclear Palsy (PSP).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Please contact the study team to discuss whether or not you are eligible to participate in a study.

Inclusion Criteria:

  • All subjects will be over age 35.
  • Must present with gradual progression of PSP-related symptoms.
  • Must have an informant to provide independent evaluation of functioning.  
  • All subjects must meet the 2017 Movement Disorder Society clinical criteria for PSP, including any of the clinical presentations of PSP such as PSP with Richardson’s syndrome, PSP with progressive gait freezing, PSP with predominant parkinsonism,  PSP with predominant frontal presentation, PSP with ocular motor dysfunction, PSP with predominant speech/language disorder and PSP with predominant CBS.
  • PSP subjects must be able to ambulate (either aided or unaided) in order to undergo the optional gait examination.

Exclusion Criteria:

  • Subjects who do not have the symptoms necessary to fulfill inclusion criteria for PSP.
  • Subjects with concurrent illnesses that could account for their symptoms such as traumatic brain injury, encephalitis, strokes or developmental syndromes.
  • Women that are pregnant or post-partum and breast-feeding.
  • All women who can become pregnant must have a pregnancy test before the PET scan.
  • Subjects undergoing the tau-PET scan due to a prolonged QT interval on ECG or if they have any of the following genetic conditions which can increase the chance of cancer:
    • Cowden disease;
    • Lynch syndrome;
    • Hypogammaglobulinemia;
    • Wiskott-Aldrich syndrome;
    • Down’s syndrome.
  • Subjects if MRI is contraindicated (metal in head, cardiac pacemaker, etc.).
  • Subjects with severe claustrophobia.
  • Subjects with conditions that may confound brain imaging studies (e.g., structural abnormalities including subdural hematoma, intracranial neoplasm or large cortical infarcts).
  • Subjects who are medically unstable or are on medications that might affect brain structure or metabolism (e.g., chemotherapy).

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Keith Josephs, M.D.

Open for enrollment

Contact information:

Sarah Boland CCRP

(507)284-3863

Boland.Sarah@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available